The mediation of platelet quiescence by NO-releasing polymers via cGMP-induced serine 239 phosphorylation of vasodilator-stimulated phosphoprotein

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8086-8096

  Major, Terry C ^a   Handa, Hitesh ^a   Brisbois, Elizabeth J ^b   Reynolds, Melissa M ^c   Annich, Gail M ^a   Meyerhoff, Mark E ^b   Bartlett, Robert H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

CGMP; Extracorporeal circulation (ECC); Hemocompatibility; Nitric oxide (NO); Platelets; Vasodilator stimulated phosphoprotein (VASP)

Indexed keywords

CGMP; EXTRACORPOREAL CIRCULATION; HEMOCOMPATIBILITY; PLATELET AGGREGATION; SIGNALING MECHANISMS; SODIUM NITROPRUSSIDE; THROMBUS FORMATION; VASODILATOR-STIMULATED PHOSPHOPROTEINS;

AMINO ACIDS; BIOMEDICAL EQUIPMENT; NITRIC OXIDE; PHOSPHORYLATION; PLASTIC COATINGS; PLATELETS; POLYMER FILMS; SIGNALING;

POLYMERS;

CYCLIC GMP; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PADGEM PROTEIN; POLYMER; SERINE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; EX VIVO STUDY; HEART RATE; HUMAN; HUMAN CELL; MEAN ARTERIAL PRESSURE; NONHUMAN; PH; PLATELET QUIESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENICITY; UPREGULATION;

ORYCTOLAGUS CUNICULUS;

CGKI; CGMP; CGMP-DEPENDENT PROTEIN KINASE TYPES I Β SUBUNIT; DBHD; DIBUTYLHEXANEDIAMINE; EXTRACORPOREAL CIRCULATION (ECC); HEMOCOMPATIBILITY; NITRIC OXIDE (NO); NO RELEASING; NOREL; P-VASP (SER 157); P-VASP (SER 239); PLATELETS; RSNO; S-NITROSOTHIOL; SERINE 157 PHOSPHORYLATION OF VASP; SERINE 239 PHOSPHORYLATION OF VASP; SGC; SNP; SODIUM NITROPRUSSIDE; SOLUBLE GUANYLATE CYCLASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP);

ANIMALS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC GMP; HUMANS; MATERIALS TESTING; MICROFILAMENT PROTEINS; NITRIC OXIDE; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYMERS; RABBITS; SERINE;

EID: 84881662455     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.041     Document Type: Article

References (32)

1. Wu B., Gerlitz B., Grinnell B.W., Meyerhoff M.E. Polymeric coatings that mimic the endothelium: combining nitric oxide release with surface-bound active thrombomodulin and heparin. Biomaterials 2007, 28:4047-4055.
2. Huang X.J., Guduru D., Xu Z.K., Vienken J., Groth T. Blood compatibility and permeability of heparin-modified polysulfone as potential membrane forsimultaneous hemodialysis and LDL removal. Macromol Biosci 2011, 11:131-140.
3. Byun Y., Jacobs H.A., Kim S.W. Binding kinetics of thrombin and antithrombin III with immobilized heparin using a spacer. ASAIO J 1992, 38:M649-M653.
4. Chen H., Chen Y., Sheardown H., Brook M.A. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials 2005, 26:7418-7424.
5. Zhou Z., Meyerhoff M.E. Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. Biomaterials 2005, 26:6506-6517.
6. Major T.C., Brant D.O., Reynolds M.M., Bartlett R.H., Meyerhoff M.E., Handa H., et al. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials 2010, 31:2736-2745.
7. Askew S.C., Butler A.R., Flitney F.W., Kemp G.D., Megson I.L. Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Bioorg Med Chem 1995, 3:1-9.
8. Stasko N.A., Fischer T.H., Schoenfisch M.H. S-nitrosothiol-modified dendrimers as nitric oxide delivery vehicles. Biomacromolecules 2008, 9:834-841.
9. Eigenthaler M., Ullrich H., Geiger J., Horstrup K., Honig-Liedl P., Wiebecke D., et al. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. JBiol Chem 1993, 268:13526-13531.
10. Goud C., DiPiero A., Lockette W.E., Webb R.C., Charpie J.R. Cyclic GMP-independent mechanisms of nitric oxide-induced vasodilation. Gen Pharmacol 1999, 32:51-55.
11. Begonja A.J., Teichmann L., Geiger J., Gambaryan S., Walter U. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis 2006, 36:166-170.
12. Leoncini G., Bruzzese D., Signorello M.G. The L-arginine/NO pathway in the early phases of platelet stimulation by collagen. Biochem Pharmacol 2005, 69:289-296.
13. Radomski M.W., Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol 1993, 344:251-264.
14. Radomski M.W., Palmer R.M., Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987, 148:1482-1489.
15. Hofmann F., Ammendola A., Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. JCell Sci 2000, 113(Pt. 10):1671-1676.
16. Lohmann S.M., Vaandrager A.B., Smolenski A., Walter U., De Jonge H.R. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 1997, 22:307-312.
17. Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., et al. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) invitro and in intact human platelets. JBiol Chem 1994, 269:14509-14517.
18. Eigenthaler M., Nolte C., Halbrugge M., Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992, 205:471-481.
19. Nolte C., Eigenthaler M., Horstrup K., Honig-Liedl P., Walter U. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors. Biochem Pharmacol 1994, 48:1569-1575.
20. Smolenski A., Bachmann C., Reinhard K., Honig-Liedl P., Jarchau T., Hoschuetzky H., et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation invitro and in intact cells using a phosphospecific monoclonal antibody. JBiol Chem 1998, 273:20029-20035.
21. Chipinda I., Simoyi R.H. Formation and stability of a nitric oxide donor: S-nitroso-N-acetylpenicillamine. JPhys Chem B 2006, 110:5052-5061.
22. Andrews R.K., Berndt M.C. Platelet physiology and thrombosis. Thromb Res 2004, 114:447-453.
23. Aktas B., Utz A., Hoenig-Liedl P., Walter U., Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: invitro and invivo/exvivo studies. Stroke 2003, 34:764-769.
24. Oelze M., Mollnau H., Hoffmann N., Warnholtz A., Bodenschatz M., Smolenski A., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000, 87:999-1005.
25. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. PNAS 1996, 93:1480-1485.
26. Vaughn M.W., Kuo L., Liao J.C. Estimation of nitric oxide production and reaction rates in tissue by use of a mathematical model. Am J Phys 1998, 274:H2163-H2176.
27. Adrian K., Skogby M., Friberg L.G., Mellgren K. The effect of s-nitroso-glutathione on platelet and leukocyte function during experimental extracorporeal circulation. Artif Organs 2003, 27:570-575.
28. Skrzypchak A.M., Lafayette N.G., Bartlett R.H., Zhou Z., Frost M.C., Meyerhoff M.E., et al. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an invivo model of extracorporeal circulation. Perfusion 2007, 22:193-200.
29. Smolenski A., Burkhardt A.M., Eigenthaler M., Butt E., Gambaryan S., Lohmann S.M., et al. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn-Schmied Arch Pharmacol 1998, 358:134-139.
30. Aszodi A., Pfeifer A., Ahmad M., Glauner M., Zhou X.H., Ny L., et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999, 18:37-48.
31. Hauser W., Knobeloch K.P., Eigenthaler M., Gambaryan S., Krenn V., Geiger J., et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. PNAS 1999, 96:8120-8125.
32. Sogo N., Magid K.S., Shaw C.A., Webb D.J., Megson I.L. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000, 279:412-419.